Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Recently, mutations of the additional sex comb-like 1 (ASXL1) gene were identified in patients with myelodysplastic syndrome (MDS), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, ASXL1 mutations were identified in 106 (22.7%) of the 466 patients with primary MDS based on the French-American-British (FAB) classification and 62 (17.1%) of the 362 patients based on the World Health Organization (WHO) classification. ASXL1 mutation was closely associated with trisomy 8 and mutations of RUNX1, EZH2, IDH, NRAS, JAK2, SETBP1 and SRSF2, but was negatively associated with SF3B1 mutation. Most ASXL1-mutated patients (85%) had concurrent other gene mutations at diagnosis. ASXL1 mutation was an independent poor prognostic factor for survival. Sequential studies showed that the original ASXL1 mutation remained unchanged at disease progression in all 32 ASXL1-mutated patients but were frequently accompanied with acquisition of mutations of other genes, including RUNX1, NRAS, KRAS, SF3B1, SETBP1 and chromosomal evolution. On the other side, among the 80 ASXL1-wild patients, only one acquired ASXL1 mutation at leukemia transformation. In conclusion, ASXL1 mutations in association with other genetic alterations may have a role in the development of MDS but contribute little to disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J., Larrayoz, M. J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., et al. (2010) · Leukemia · doi:10.1038/leu.2010.20 · Cited by 264
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Cited by
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
“Mutations in ASXL1, RUNX1, and STAG2 tend to co-occur in myelodysplastic syndromes.35 At 2 months before receiving a diagnosis of AML, Participant 2 carried 2 mutations in CEBPA: an in-frame C-terminal 33-bp insertion and a frame-shift N-terminal deletion.”
BackgroundInfluentialHou, H.-A., Chou, W.-C., Kuo, Y.-Y., Liu, C.-Y., Lin, L.-I., Tseng, M.-H., Chiang, Y.-C., Liu, M.-C., Liu, C.-W., Tang, J.-L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.59 · Cited by 164
Self-citationGain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Yang, H., Kurtenbach, S., Guo, Y., Lohse, I., Durante, M. A., Li, J., Li, Z., Al-Ali, H., Li, L., Chen, Z., et al. (2018) · Blood · doi:10.1182/blood-2017-06-789669 · Cited by 163
Nagase, R., Inoue, D., Pastore, A., Fujino, T., Hou, H.-A., Yamasaki, N., Goyama, S., Saika, M., Kanai, A., Sera, Y., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171151 · Cited by 155
Self-citationYang, Y.-T., Chiu, Y.-C., Kao, C.-J., Hou, H.-A., Lin, C.-C., Tsai, C.-H., Tseng, M.-H., Chou, W.-C., & Tien, H.-F. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0115-2 · Cited by 32
Self-citation
Metadata
- Authors
- Chen, T.-C., Hou, H.-A., Chou, W.-C., Tang, J.-L., Kuo, Y.-Y., Chen, C.-Y., Tseng, M.-H., Huang, C.-F., Lai, Y.-J., Chiang, Y.-C., Lee, F.-Y., Liu, M.-C., Liu, C.-W., Liu, C.-Y., Yao, M., Huang, S.-Y., Ko, B.-S., Hsu, S.-C., Wu, S.-J., Tsay, W., Chen, Y.-C., & Tien, H.-F.
- Venue
- Blood Cancer Journal
- Published
- 2014-01-17
- Volume
- 4
- Issue
- 1
- Pages
- e177-e177
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W1993226749
- Cited by
- 96
- References
- 6
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.